title: Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results.
abstract: OBJECTIVE
  To present the preliminary results of stereotactic body radiotherapy (SBRT) for lung oligometastases originated from colorectal cancer (CRC).
  
  
  METHODS
  Thirteen patients (9 male, 4 female) with lung oligometastases from CRC were prospectively selected for SBRT between July 2009 and July 2013. We used a dose risk-adapted schedule of radiation.
  
  
  RESULTS
  The median follow-up was 9.16 months (range 2-45.6). The median age was 69 years (range 40-84). Three cases (23.1%) were treated with 12.5 Gy in 4 fractions (112.5 biological effective dose/BED). Four cases (30.8%) received 18Gy (151.2 BED), 2 (15.4%) 7.5 Gy in 8 fractions (BED 105) and 4 (30.8%) a monofraction of 34 Gy (149.6 BED). There were 5 (38.5%) complete responses, 5 (38.5%) partial responses and 3 (23%) patients remained with stable disease. During follow-up 6 patients (46.2%) showed distant metastases: liver (N=3, 50%), bone (N=1, 16.6%) and contralateral lung (N=2, 33.3%). Median time to systemic progression was 9 months. One- and two-year distant progression-free survival (DPFS) was 45.8% and 22.9%, respectively. Local control (LC), overall survival (OS), and cause-specific survival (CSS) at one- and two-years were all 92.3%. A tendency for a better local response and DFPS in patients aged ≤70 years and BED > 120 Gy was observed. No grade 3-4 toxicity was noticed.
  
  
  CONCLUSIONS
  Excellent LC and longer DFS could be achieved with SBRT in oligometastatic lung disease from CRC, delaying thus disease progression and the need for further treatment.
authors.affiliation: Cruces University Hospital, Radiation Oncology Department, Barakaldo, Vizcaya (Basque Country), Spain.
authors.forename: Claudia
authors.initials: C
authors.lastname: Carvajal
authors.forename: Arturo
authors.initials: A
authors.lastname: Navarro-Martin
authors.forename: Jon
authors.initials: J
authors.lastname: Cacicedo
authors.forename: Ricard
authors.initials: R
authors.lastname: Ramos
authors.forename: Ferran
authors.initials: F
authors.lastname: Guedea
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D059146:Metastasectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016634:Radiosurgery / Q000009:adverse effects / Q000401:mortality; D012074:Remission Induction; D012307:Risk Factors; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome